---
title: "AbbVie's new HIV drug Class 1 approved for clinical trials in China"
description: "On July 29th, the China National Medical Products Administration's Center for Drug Evaluation (CDE) website announced that AbbVie's Class 1 new drug ABBV-382 injection has been approved for clinical t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/210055647.md"
published_at: "2024-07-29T06:04:03.000Z"
---

# AbbVie's new HIV drug Class 1 approved for clinical trials in China

> On July 29th, the China National Medical Products Administration's Center for Drug Evaluation (CDE) website announced that AbbVie's Class 1 new drug ABBV-382 injection has been approved for clinical trials. It is intended to be developed for the continuous suppression of immune-mediated HIV (HIV plasma viral load at undetectable levels) without combination antiretroviral therapy (ART). Public information shows that ABBV-382 is an α4β7 integrin monoclonal antibody, currently in phase 2 clinical trials globally. This is the first time this investigational drug has been approved for clinical trials in China. According to AbbVie's official website, the company is developing a combination of ABBV-181 (budigalimab, anti-PD-1) and ABBV-382 (research code: ABBV-1882), studying it as an HIV virus control regimen for antiretroviral therapy (ART), currently in phase 2 clinical trials

According to the Zhitong Finance and Economics APP, on July 29th, the China National Medical Products Administration Drug Evaluation Center (CDE) official website announced that AbbVie (ABBV.US) Class 1 new drug ABBV-382 injection was approved for clinical trials. It is intended to be developed for the continuous suppression of immune-mediated HIV (HIV plasma viral load at undetectable levels) without combination antiretroviral therapy (ART). Public information shows that ABBV-382 is an α4β7 integrin monoclonal antibody, currently in phase 2 clinical trials globally, and this is the first time this investigational drug has been approved for clinical trials in China.

![Image](https://imageproxy.pbkrs.com/http://img.zhitongcaijing.com/images/contentformat/3207592534a5c0c5ba703f3e6252bac9.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

According to AbbVie's official website, the company is developing a combination of ABBV-181 (budigalimab, anti-PD-1) and ABBV-382 (research code: ABBV-1882), studying it as an antiretroviral therapy (ART) for HIV virus control, currently in phase 2 clinical trials

### Related Stocks

- [ABBV.US - Abbvie](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GWN Securities Inc. Sells 61,072 Shares of AbbVie Inc. $ABBV | GWN Securities Inc. significantly reduced its stake in AbbVie Inc. by 91.8%, selling 61,072 shares during Q2, leaving it | [Link](https://longbridge.com/en/news/263051037.md) |
| AbbVie Inc. $ABBV Shares Bought by Pinnacle Associates Ltd. | Pinnacle Associates Ltd. increased its stake in AbbVie Inc. (NYSE:ABBV) by 28.4% in Q2, owning 168,560 shares valued at  | [Link](https://longbridge.com/en/news/263707865.md) |
| IronBridge Private Wealth LLC Has $905,000 Holdings in Apple Inc. $AAPL | IronBridge Private Wealth LLC reduced its stake in Apple Inc. (NASDAQ:AAPL) by 77.3% in Q3, holding 3,555 shares valued  | [Link](https://longbridge.com/en/news/276436345.md) |
| Rocket Lab Corporation $RKLB Stock Holdings Increased by Vanguard Group Inc. | Vanguard Group Inc. increased its stake in Rocket Lab Corporation (NASDAQ:RKLB) by 5.4% in Q3, owning 41.8 million share | [Link](https://longbridge.com/en/news/276451972.md) |
| Alphabet Inc. $GOOG Shares Sold by Fifth Third Bancorp | Fifth Third Bancorp reduced its stake in Alphabet Inc. (NASDAQ:GOOG) by 0.4% in Q3, now holding 1,185,382 shares valued  | [Link](https://longbridge.com/en/news/276432399.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
